Literature DB >> 29025132

Most Relevant Neuropathic Pain Treatment and Chronic Low Back Pain Management Guidelines: A Change Pain Latin America Advisory Panel Consensus.

Cesar Amescua-Garcia1, Frantz Colimon2, Carlos Guerrero3, Aziza Jreige Iskandar4, Maria Berenguel Cook5, Patricia Bonilla6, Durval Campos Kraychete7, William Delgado Barrera8, Jose Alberto Flores Cantisani9, John Jairo Hernandez-Castro10, Argelia Lara-Solares11, Concepcion Perez Hernandez12, Maria Antonieta Rico13, Maria Del Rocio Guillen Nunez14, Manuel Sempertegui Gallegos15, Joao Batista Santos Garcia16.   

Abstract

Objective: Chronic pain conditions profoundly affect the daily living of a significant number of people and are a major economic and social burden, particularly in developing countries. The Change Pain Latin America (CPLA) advisory panel aimed to identify the most appropriate guidelines for the treatment of neuropathic pain (NP) and chronic low back pain (CLBP) for use across Latin America.
Methods: Published systematic reviews or practice guidelines were identified by a systematic search of PubMed, the Guidelines Clearinghouse, and Google. Articles were screened by an independent reviewer, and potential candidate guidelines were selected for more in-depth review. A shortlist of suitable guidelines was selected and critically evaluated by the CPLA advisory panel.
Results: Searches identified 674 and 604 guideline articles for NP and CLBP, respectively. Of these, 14 guidelines were shortlisted for consensus consideration, with the following final selections made: "Recommendations for the pharmacological management of neuropathic pain from the Neuropathic Pain Special Interest Group in 2015-pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis.""Diagnosis and treatment of low back pain: A joint clinical practice guideline from the American College of Physicians and the American Pain Society" (2007). Conclusions: The selected guidelines were endorsed by all members of the CPLA advisory board as the best fit for use across Latin America. In addition, regional considerations were discussed and recorded. We have included this expert local insight and advice to enhance the implementation of each guideline across all Latin American countries.

Entities:  

Mesh:

Year:  2018        PMID: 29025132     DOI: 10.1093/pm/pnx198

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  5 in total

1.  Mirogabalin in Japanese Patients with Renal Impairment and Pain Associated with Diabetic Peripheral Neuropathy or Post-Herpetic Neuralgia: A Phase III, Open-Label, 14-Week Study.

Authors:  Masayuki Baba; Hiroshi Takatsuna; Norimitsu Matsui; Shoichi Ohwada
Journal:  J Pain Res       Date:  2020-07-17       Impact factor: 3.133

2.  Acute Tramadol-Induced Cellular Tolerance and Dependence of Ventral Tegmental Area Dopaminergic Neurons: An In Vivo Electrophysiological Study.

Authors:  Shabnam Khodayari; Firouz Ghaderi Pakdel; Parviz Shahabi; Somayyeh Naderi
Journal:  Basic Clin Neurosci       Date:  2019-05-01

3.  Evaluation of Treatment Patterns and Direct Costs Associated with the Management of Neuropathic Pain.

Authors:  Manuel E Machado-Duque; Andres Gaviria-Mendoza; Jorge E Machado-Alba; Natalia Castaño
Journal:  Pain Res Manag       Date:  2020-03-30       Impact factor: 3.037

4.  17β-Estradiol Attenuates Neuropathic Pain Caused by Spared Nerve Injury by Upregulating CIC-3 in the Dorsal Root Ganglion of Ovariectomized Rats.

Authors:  Zhen-Zhen Xu; Qin-Yi Chen; Shi-Yu Deng; Meng Zhang; Chao-Yang Tan; Ke-Tao Ma; Li Li; Jun-Qiang Si; Li-Cang Zhu
Journal:  Front Neurosci       Date:  2019-11-08       Impact factor: 4.677

5.  Are clinical practice guidelines for low back pain interventions of high quality and updated? A systematic review using the AGREE II instrument.

Authors:  G Castellini; V Iannicelli; M Briguglio; D Corbetta; L M Sconfienza; G Banfi; S Gianola
Journal:  BMC Health Serv Res       Date:  2020-10-22       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.